References
- Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globoscan 2000. Int J Cancer 2001; 94:153–6.
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008;359:378–90.
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
- Lenciono R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
- Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: A case report. J Clin Oncol 2011;29:e330–2.
- Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression induced by sorafenib of locally advanced HCC allowing curative resection. Liver Int 2011;31:740–3.
- Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009; 9:2851–4.
- Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78(Suppl 1): 154–66.
- Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART?. A case report. Med Oncol 2011;28(Suppl 1):S165–8.
- Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, et al. Complete response for advanced liver cancer during sorafenib therapy: Case report. BMC Gastroenterol 2011;11:4.
- Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World J Gastroenterol 2011;17:2450–3.
- So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 2008;1:18.
- Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report. Target Oncol 2010;5:59–63.
- Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: A case report. Oncology 2011; 81(Suppl 1):152–7.